Niagen Bioscience Inc
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Niagen Bioscience Inc (Ticker: NAGE) develops and commercializes innovative bioscience products focused on cellular health and energy metabolism, primarily through nicotinamide riboside (NR) branded as Niagen, a clinically validated precursor to NAD+ that supports mitochondrial function and healthy aging. The company offers Niagen in various formulations, including bulk ingredients for dietary supplements, branded consumer products such as capsules and powders, and custom formulations for sports nutrition and longevity markets; it also provides research-grade Niagen for clinical studies and contract manufacturing services for NAD+-boosting nutraceuticals. Headquartered in Reno, Nevada, Niagen Bioscience was founded in 2013 as part of the ChromaDex ecosystem before spinning out as an independent entity, with operations spanning North America, Europe, and Asia-Pacific targeting supplement manufacturers, healthcare professionals, and direct-to-consumer channels in the nutraceutical and wellness industries. In late 2024, the company completed a significant uplisting to NASDAQ under ticker NAGE following a reverse merger, enhancing its capital access for global expansion; it announced a strategic partnership with a leading Asian distributor to accelerate Niagen adoption in the high-growth longevity market and launched Niagen Pro, a professional-grade line for practitioners in 2025. Niagen Bioscience continues to invest in R&D for next-generation NAD+ precursors amid rising demand for anti-aging interventions, with no major subsidiaries but key alliances with contract manufacturers worldwide.
Niagen Bioscience to Report Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Niagen Bioscience Appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research
Niagen Bioscience, Inc. (NAGE) Discusses Strategic Expansion Into Pharmaceutical Development and NB4168 Drug Program Transcript
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience CEO Rob Fried to Participate in Virtual Fireside Chat to Discuss Pharmaceutical Strategy on July 15, 2026
Niagen Bioscience Launches Pharmaceutical Program for Accelerated Aging and Rare Genetic Diseases
Implied Volatility Surging for Niagen Bioscience Stock Options
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy
Niagen: High-Quality Growth At A Fair Price